Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRPR theranostic pair
- Development stage
- Preclinical
- Lead developer
- Fuzionaire Theranostics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
The GRPR theranostic pair is a radiopharmaceutical program being developed by Fuzionaire Radioisotope Technologies (formerly Fuzionaire Diagnostics) that targets the gastrin-releasing peptide receptor (GRPR) for both imaging and treatment of cancer. The program utilizes the company's proprietary HetSiFA (heteroaromatic silicon-fluoride acceptor) platform technology to create chemically identical diagnostic and therapeutic pairs. For imaging, the program uses fluorine-18 (18F) and gallium-68 (68Ga) radiolabeled ligands for PET scanning, while for therapy it employs lutetium-177 (177Lu), terbium-161 (161Tb), and actinium-225 (225Ac) radionuclides for targeted radioligand therapy. The primary indications are metastatic prostate cancer and ER-positive breast cancer, with GRPR serving as a complementary target to the widely used PSMA target in prostate cancer. The program is currently in preclinical development, with plans for first patient tests under compassionate use laws in Germany.
- Other names
- GRPR-targeted theranostic
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on GRPR theranostic pair.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRPR theranostic pair.